Profile data is unavailable for this security.
About the company
Jubilant Pharmova Limited is an India-based integrated pharmaceutical company. The Company’s segments include Radiopharma, Allergy Immunotherapy, Contract Development and Manufacturing Organisation-Sterile Injectables, Generics, Contract Research, Development and Manufacturing Organisation, Proprietary Novel Drugs, and Management Services. The Radiopharma segment comprises radiopharmaceuticals including radio pharmacies. The Contract Development and Manufacturing Organisation-Sterile Injectables segment includes contract development and manufacturing organisation-sterile injectables products. The Generics segment includes solid dosage formulations. The Contract Research, Development and Manufacturing Organisation segment includes drug discovery services, and active pharmaceutical ingredients. The Proprietary Novel Drugs segment includes patient-focused biopharmaceutical business working to address unmet medical needs in oncology and autoimmune diseases.
- Revenue in INR (TTM)68.48bn
- Net income in INR5.53bn
- Incorporated1978
- Employees995.00
- LocationJubilant Pharmova Ltd1A, Sector 16ANOIDA 201301IndiaIND
- Phone+91 1 204361000
- Fax+91 1 204234881
- Websitehttps://www.jubl.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Strides Pharma Science Ltd | 42.09bn | -475.19m | 118.30bn | 3.07k | -- | -- | 85.63 | 2.81 | -5.44 | 0.4871 | 460.14 | -- | -- | -- | -- | 13,731,270.00 | -- | -1.68 | -- | -2.97 | 60.18 | 51.39 | -1.68 | -3.36 | -- | 1.24 | -- | -- | 9.83 | 13.21 | 43.57 | -- | -18.52 | -3.58 |
| Granules India Ltd | 47.01bn | 4.92bn | 130.85bn | 4.12k | 26.61 | -- | 18.61 | 2.78 | 20.29 | 20.29 | 193.87 | -- | -- | -- | -- | 11,403,970.00 | -- | 10.68 | -- | 16.18 | 56.89 | 48.83 | 10.47 | 11.82 | -- | 6.95 | -- | 8.96 | -0.123 | 14.61 | -21.54 | 11.38 | 6.38 | 8.45 |
| Akums Drugs and Pharmaceuticals Ltd | -100.00bn | -100.00bn | 134.06bn | 7.39k | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 14.32 | -- | -104.25 | -- | -- | -- |
| Glenmark Life Sciences Ltd | 22.93bn | 4.47bn | 141.13bn | 2.01k | 31.64 | -- | 28.11 | 6.15 | 36.41 | 36.41 | 186.81 | -- | -- | -- | -- | 11,387,190.00 | -- | 18.28 | -- | 29.99 | 54.58 | 53.40 | 19.49 | 20.23 | -- | 389.45 | -- | 26.37 | 5.64 | 20.83 | 0.841 | 19.21 | 69.11 | -- |
| Marksans Pharma Ltd | 22.68bn | 3.34bn | 144.26bn | 2.00k | 43.18 | -- | 34.80 | 6.36 | 7.37 | 7.37 | 50.09 | -- | -- | -- | -- | 11,339,960.00 | -- | 14.62 | -- | 18.52 | 53.39 | 50.52 | 14.71 | 14.03 | -- | 32.19 | -- | 6.17 | 17.56 | 16.84 | 17.80 | 32.62 | 73.86 | 64.38 |
| Caplin Point Laboratories Ltd | 17.58bn | 4.78bn | 147.43bn | 859.00 | 30.95 | -- | 27.30 | 8.39 | 62.67 | 62.67 | 230.62 | -- | -- | -- | -- | 20,462,630.00 | -- | 19.83 | -- | 22.82 | 58.41 | 53.38 | 27.43 | 25.39 | -- | 1,525.59 | -- | 9.06 | 15.50 | 21.17 | 21.48 | 20.95 | 17.47 | 17.84 |
| Wockhardt Ltd | 28.93bn | -3.43bn | 158.40bn | 2.39k | -- | -- | -- | 5.48 | -23.75 | -23.75 | 199.60 | -- | -- | -- | -- | 12,084,380.00 | -- | -4.56 | -- | -8.29 | 58.66 | 55.26 | -12.17 | -12.70 | -- | 0.0764 | -- | -- | 5.55 | -4.73 | 17.17 | -- | -4.71 | -- |
| Neuland Laboratories Ltd. | 16.35bn | 3.36bn | 163.85bn | 1.65k | 48.76 | -- | 41.12 | 10.02 | 261.94 | 261.94 | 1,274.50 | -- | -- | -- | -- | 9,922,259.00 | -- | 9.25 | -- | 12.71 | 53.32 | 47.81 | 20.55 | 11.99 | -- | 29.52 | -- | 7.13 | 30.84 | 18.51 | 83.51 | 78.76 | 17.88 | 63.45 |
| Sanofi India Ltd | 23.83bn | 4.30bn | 166.05bn | 2.17k | 38.64 | 24.26 | 35.48 | 6.97 | 186.62 | 229.86 | 1,034.61 | 297.26 | 1.67 | 2.73 | 15.60 | 10,960,440.00 | 30.08 | 22.42 | 57.55 | 30.21 | 55.95 | 55.52 | 18.04 | 21.03 | 0.8140 | 435.86 | 0.0313 | 135.49 | 2.92 | 0.573 | -2.85 | 9.64 | -10.34 | 14.73 |
| Astrazeneca Pharma India Ltd | 13.88bn | 958.59m | 171.82bn | 940.00 | 179.24 | -- | 154.92 | 12.38 | 38.34 | 38.34 | 555.18 | -- | -- | -- | -- | 14,761,520.00 | -- | 11.78 | -- | 19.62 | 48.51 | 54.64 | 6.91 | 10.27 | -- | 121.25 | -- | 25.62 | 29.17 | 12.21 | 62.66 | 24.29 | -10.46 | -- |
| Eris Lifesciences Ltd | 22.62bn | 3.80bn | 185.98bn | 3.08k | 48.96 | -- | 30.47 | 8.22 | 27.91 | 27.91 | 166.06 | -- | -- | -- | -- | 7,344,939.00 | -- | 13.42 | -- | 16.80 | 78.68 | 79.98 | 17.36 | 24.96 | -- | 4.20 | -- | -- | 19.23 | 15.39 | 2.57 | 6.15 | 27.72 | -- |
| Jubilant Pharmova Ltd | 68.48bn | 5.53bn | 190.99bn | 995.00 | 34.59 | -- | 20.51 | 2.79 | 34.86 | 34.86 | 432.21 | -- | -- | -- | -- | 68,821,100.00 | -- | 2.96 | -- | 3.55 | 68.13 | 68.47 | 8.01 | 5.13 | -- | 2.34 | -- | 24.73 | 6.70 | -5.95 | 226.43 | -33.08 | 6.48 | 2.13 |
| Alembic Pharmaceuticals Ltd | 63.04bn | 6.30bn | 219.16bn | 14.86k | 34.80 | -- | 24.21 | 3.48 | 32.04 | 32.04 | 320.63 | -- | -- | -- | -- | 4,242,974.00 | -- | 10.72 | -- | 14.25 | 73.10 | 65.98 | 9.99 | 12.47 | -- | 12.52 | -- | 28.29 | 10.19 | 9.62 | 80.07 | 1.05 | -15.59 | 14.87 |
| Pfizer Ltd | 22.25bn | 6.09bn | 249.64bn | 1.72k | 41.03 | -- | 37.27 | 11.22 | 133.01 | 133.01 | 486.27 | -- | -- | -- | -- | 12,926,610.00 | -- | 14.22 | -- | 17.71 | 65.06 | 61.37 | 27.35 | 24.05 | -- | 43.74 | -- | 82.67 | -9.55 | 1.05 | -11.64 | 5.14 | 33.35 | 9.24 |
| Laurus Labs Ltd | 50.54bn | 1.48bn | 251.98bn | 6.01k | 170.39 | -- | 45.59 | 4.99 | 2.74 | 2.74 | 93.40 | -- | -- | -- | -- | 8,413,434.00 | -- | 10.13 | -- | 16.47 | 52.80 | 47.63 | 3.01 | 12.83 | -- | 2.04 | -- | 13.00 | -16.55 | 17.07 | -79.68 | 11.36 | 21.68 | 21.67 |
| Natco Pharma Ltd. | 42.21bn | 16.37bn | 265.28bn | 4.02k | 16.21 | -- | 14.54 | 6.28 | 91.37 | 91.37 | 235.68 | -- | -- | -- | -- | 10,510,210.00 | -- | 12.33 | -- | 14.25 | 83.40 | 73.05 | 38.77 | 25.16 | -- | 91.13 | -- | 18.96 | 47.72 | 13.81 | 94.09 | 16.59 | -5.76 | 14.87 |
Data as of Sep 20 2024. Currency figures normalised to Jubilant Pharmova Ltd's reporting currency: Indian Rupee INR
17.41%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| East Bridge Capital Management L.P.as of 18 Sep 2024 | 8.72m | 5.48% |
| Norges Bank Investment Managementas of 30 Sep 2023 | 6.30m | 3.96% |
| quant Money Managers Ltd.as of 30 Aug 2024 | 3.06m | 1.92% |
| The Vanguard Group, Inc.as of 04 Sep 2024 | 3.04m | 1.91% |
| Abakkus Asset Manager LLPas of 30 Sep 2023 | 1.91m | 1.20% |
| Dimensional Fund Advisors LPas of 05 Sep 2024 | 1.90m | 1.19% |
| BlackRock Fund Advisorsas of 05 Sep 2024 | 1.08m | 0.68% |
| HBM Partners AG (Investment Management)as of 31 Mar 2024 | 835.52k | 0.53% |
| Kotak Mahindra Asset Management Co. Ltd.as of 31 Aug 2024 | 590.00k | 0.37% |
| BlackRock Advisors (UK) Ltd.as of 05 Sep 2024 | 291.99k | 0.18% |
More ▼
Data from 31 Mar 2024 - 18 Sep 2024Source: FactSet Research Systems Inc.
